Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and prognostic determinants of BTK inhibitors in chronic lymphocytic leukemia (CLL): A real-world single-center cohort study from China

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYongqiang WeiXWXiaolei WeiRFRu Feng

Discussion

Loading...

Member takes

Overview

Retrospective cohort study highlights first-line treatment with BTK inhibitors improves progression-free survival in CLL patients, suggesting adherence is crucial.

Key Points

  • The study aims to evaluate the efficacy and prognostic factors of BTK inhibitors in chronic lymphocytic leukemia among Chinese patients.
  • Conducted a retrospective cohort study of CLL patients at Nanfang Hospital from 2014 to 2024
  • Included adults with confirmed CLL who received at least one dose of a BTK inhibitor
  • Analyzed demographic, clinical, and laboratory data, focusing on progression-free survival and overall survival
  • Median follow-up was 1.8 years with high 5-year progression-free survival at 80.7%
  • TP53 mutations and complex karyotype were linked to inferior progression-free survival
  • Treatment adherence was vital, with suspension of BTK inhibitors negatively impacting overall survival

Cite This Study

Wei et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbfehttps://doi.org/10.1182/blood-2025-7421
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical Safety Profile of Bruton’s Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India2026
  2. 2A predictive model for treatment failure in CLL/SLL patients receiving BTK inhibitor: A multi-center retrospective study2025
  3. 3Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center2025
  4. 4Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center2025
  5. 5Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy2025